bioAffinity Technologies, Inc. (BIAF)
$3.63-6.92%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $16M
- Beta
- -1.11
- P/E (TTM)
- -0.03
- Short % float
- 2.61%
- Days to cover
- 1.0
- SI change
- +62.3%
- 1W
- -40.10%
- 1M
- -54.22%
- vs SPY 1W
- -39.96%
- vs SPY 1M
- -56.73%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 11
- GROWTH
- 25
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-154.4%
REV YoY-
ROE-257.3%
EPS YoY-
ROA-199.3%
GROSS-40
OP-210
NET-257
[VALUATION]
P/E TTM-0.03
P/E FWD-
SECTOR PE20.34
INDUSTRY PE31.41
P/B0.34
P/FCF-
EV/EBITDA-0.04
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E38.08
ALTMAN Z-
CURR RATIO1.44
ND/EBITDA-
BETA-1.11
Company news
FAQ
- What is LOPJLB’s current signal on BIAF?
- LOPJLB’s latest quantitative signal on bioAffinity Technologies, Inc. (BIAF) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BIAF in?
- bioAffinity Technologies, Inc. (BIAF) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does bioAffinity Technologies, Inc. (BIAF) do?
- As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular leve…